Research Medical autologous fibrinogen sealant to enter clinicals for hemostasis.
This article was originally published in The Gray Sheet
Executive SummaryRESEARCH MEDICAL'S AUTOLOGOUS FIBRINOGEN DELIVERY KIT U.S. CLINICALS, which are slated to begin this month at the University of New York at Stony Brook, will evaluate use of the AFD kit as a means of achieving topical hemostasis for the treatment of excessive bleeding from the donor skin site of burn patients. The company received an FDA investigational device exemption in April for the feasibility study, which will involve 12 to 15 subjects.
You may also be interested in...
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.